論文

(3)マイクロRNAの解析

MicroRNA-8073: Tumor suppressor and potential therapeutic treatment.
Mizoguchi A1, Takayama A1, Arai T1, Kawauchi J1, Sudo H1.
PLoS One. 2018 Dec 27;13(12):e0209750. doi: 10.1371/journal.pone.0209750. eCollection 2018.
https://www.ncbi.nlm.nih.gov/pubmed/30589909

Expression profile of miR-17/92 cluster is predictive of treatment response in rectal cancer.
Kral J, Korenkova V, Novosadova V, Langerova L, Schneiderova M, Liska V, Levy M, Veskrnova V, Spicak J, Opattova A, Jiraskova K, Vymetalkova V, Vodicka P, Slyskova J.
Carcinogenesis. 2018 Oct 1. doi: 10.1093/carcin/bgy100
https://www.ncbi.nlm.nih.gov/pubmed/30277504

A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder.
Inamoto T1, Uehara H1, Akao Y2, Ibuki N1, Komura K1, Takahara K1, Takai T1, Uchimoto T1, Saito K1, Tanda N1, Yoshikawa Y1, Minami K1, Hirano H1, Nomi H1, Kato R3, Hayashi T3, Azuma H1.
Dis Markers. 2018 Jun 20;2018:5468672. doi: 10.1155/2018/5468672. eCollection 2018
https://www.ncbi.nlm.nih.gov/pubmed/30026881

Circulating exosomes suppress the induction of regulatory T cells via let-7i in multiple sclerosis.
Kimura K, Hohjoh H, Fukuoka M, Sato W, Oki S, Tomi C, Yamaguchi H, Kondo T, Takahashi R, Yamamura T.
Nat Commun. 2018 Jan 2;9(1):17. doi: 10.1038/s41467-017-02406-2.
https://www.ncbi.nlm.nih.gov/pubmed/29295981

The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo.
Fujihara S, Morishita A, Ogawa K, Tadokoro T, Chiyo T, Kato K, Kobara H, Mori H, Iwama H, Masaki T.
Oncotarget. 2017 Jan 31;8(5):8536-8549.
https://www.ncbi.nlm.nih.gov/pubmed/28052030

Cluster microRNAs miR-194 and miR-215 suppress the tumorigenicity of intestinal tumor organoids.
Nakaoka T, Saito Y, Shimamoto Y, Muramatsu T, Kimura M, Kanai Y, Saito H.
Cancer Sci. 2017 Jan 16
https://www.ncbi.nlm.nih.gov/pubmed/28092415

Repression of microRNA Function Mediates Inflammation-associated Colon Tumorigenesis.
Yoshikawa T, Wu J, Otsuka M, Kishikawa T, Suzuki N, Takata A, Ohno M, Ishibashi R, Yamagami M, Nakagawa R, Kato N, Miyazawa M, Han J, Koike K.
Gastroenterology. 2016 Nov 5. pii: S0016-5085(16)35322-7
https://www.ncbi.nlm.nih.gov/pubmed/27825961

Gene Signature-Based Development of ELISA Assays for Reproducible Qualification of Cultured Human Corneal Endothelial Cells.
Ueno M, Asada K, Toda M, Schlotzer-Schrehardt U, Nagata K, Montoya M, Sotozono C, Kinoshita S, Hamuro J.
Invest Ophthalmol Vis Sci. 2016 Aug 1;57(10):4295-305.
https://www.ncbi.nlm.nih.gov/pubmed/27552407

Histone Deacetylase Inhibition in Prostate Cancer Triggers miR-320-Mediated Suppression of the Androgen Receptor.
Sato S, Katsushima K, Shinjo K, Hatanaka A, Ohka F, Suzuki S, Naiki-Ito A, Soga N, Takahashi S, Kondo Y.
Cancer Res. 2016 Jul 15;76(14):4192-204.
https://www.ncbi.nlm.nih.gov/pubmed/27216188

The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: Study of the microRNAs associated with the antitumor effect of metformin.
Oncol Rep. 2016 Mar;35(3):1582-92.
Kato K, Iwama H, Yamashita T, Kobayashi K, Fujihara S, Fujimori T, Kamada H, Kobara H, Masaki T.
https://www.ncbi.nlm.nih.gov/pubmed/26708419

Antitumor effect of metformin on cholangiocarcinoma: In vitro and in vivo studies.
Oncol Rep. 2015 Dec;34(6):2987-96.
Fujimori T, Kato K, Fujihara S, Iwama H, Yamashita T, Kobayashi K, Kamada H, Morishita A, Kobara H, Mori H, Okano K, Suzuki Y, Masaki T.
https://www.ncbi.nlm.nih.gov/pubmed/26398221

Differences in miRNA expression profiles between GIST and leiomyoma in human samples acquired by submucosal tunneling biopsy.
Fujita K, Kobara H, Mori H, Fujihara S, Chiyo T, Matsunaga T, Nishiyama N, Ayaki M, Yachida T, Morishita A, Fujiwara M, Okano K, Suzuki Y, Iwama H, Masaki T.
Endosc Int Open. 2015 Dec;3(6):E665-71
http://www.ncbi.nlm.nih.gov/pubmed/26716134

Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest.
Kobayashi K, Morishita A, Iwama H, Fujita K, Okura R, Fujihara S, Yamashita T, Fujimori T, Kato K, Kamada H, Niki T, Hirashima M, Okano K, Suzuki Y, Masaki T.
Oncol Rep. 2015 Oct;34(4):1761-70.
https://www.ncbi.nlm.nih.gov/pubmed/26260906

miR-487b, miR-3963 and miR-6412 delay myogenic differentiation in mouse myoblast-derived C2C12 cells.
Katase N, Terada K, Suzuki T, Nishimatsu S, Nohno T.
BMC Cell Biol. 2015 Apr 30;16:13.
http://www.ncbi.nlm.nih.gov/pubmed/25925429

Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo.
Fujita K, Iwama H, Sakamoto T, Okura R, Kobayashi K, Takano J, Katsura A, Tatsuta M, Maeda E, Mimura S, Nomura T, Tani J, Miyoshi H, Morishita A, Yoneyama H, Yamana Y, Himoto T, Okano K, Suzuki Y, Niki T, Hirashima M, Masaki T.
Int J Oncol. 2015;46(6):2419-30.
https://www.ncbi.nlm.nih.gov/pubmed/25823465

MicroRNA profiles following metformin treatment in a mouse model of non-alcoholic steatohepatitis.
Katsura A, Morishita A, Iwama H, Tani J, Sakamoto T, Tatsuta M, Toyota Y, Fujita K, Kato K, Maeda E, Nomura T, Miyoshi H, Yoneyama H, Himoto T, Fujiwara S, Kobara H, Mori H, Niki T, Ono M, Hirashima M, Masaki T.
Int J Mol Med. 2015 Apr;35(4):877-84.
http://www.ncbi.nlm.nih.gov/pubmed/25672270

Identification of a MicroRNA Signature for the Diagnosis of Fibromyalgia.
Cerda-Olmedo G, Mena-Duran AV, Monsalve V, Oltra E.
PLoS One. 2015 Mar 24;10(3):e0121903.
http://www.ncbi.nlm.nih.gov/pubmed/25803872

Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer.
Hiraki M, Nishimura J, Takahashi H, Wu X, Takahashi Y, Miyo M, Nishida N, Uemura M, Hata T, Takemasa I, Mizushima T, Soh JW, Doki Y, Mori M, Yamamoto H.
Mol Ther Nucleic Acids. 2015 Mar 10;4:e231.
http://www.ncbi.nlm.nih.gov/pubmed/25756961

Involvement of miR-518c-5p to growth and metastasis in oral cancer.
Kinouchi M, Uchida D, Kuribayashi N, Tamatani T1, Nagai H, Miyamoto Y.
PLoS One. 2014 Dec 23;9(12):e115936.
http://www.ncbi.nlm.nih.gov/pubmed/25536052

microRNA regulation of endothelin-1 mRNA in renal collecting duct cells.
Jacobs ME, Jeffers LA, Welch AK, Wingo CS, Cain BD.
Life Sci. 2014 Nov 24;118(2):195-9.
http://www.ncbi.nlm.nih.gov/pubmed/24632479

Distinct microRNA expression profiles in mouse renal cortical tissue after 177Lu-octreotate administration.
Schuler E, Parris TZ, Helou K, Forssell-Aronsson E.
PLoS One. 2014 Nov 11;9(11):e112645.
http://www.ncbi.nlm.nih.gov/pubmed/25386939

Decreased miR-26a Expression Correlates with the Progression of Podocyte Injury in Autoimmune Glomerulonephritis.
Ichii O, Otsuka-Kanazawa S, Horino T, Kimura J, Nakamura T, Matsumoto M, Toi M, Kon Y.
PLoS One. 2014 Oct 17;9(10):e110383.
http://www.ncbi.nlm.nih.gov/pubmed/25329154

MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer.
Hasegawa S, Eguchi H, Nagano H, Konno M, Tomimaru Y, Wada H, Hama N, Kawamoto K, Kobayashi S, Nishida N, Koseki J, Nishimura T, Gotoh N, Ohno S, Yabuta N, Nojima H, Mori M, Doki Y, Ishii H.
Br J Cancer. 2014 Oct 14;111(8):1572-80.
http://www.ncbi.nlm.nih.gov/pubmed/25117811

Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis.
Takaki Y, Saito Y, Takasugi A, Toshimitsu K, Yamada S, Muramatsu T, Kimura M, Sugiyama K, Suzuki H, Arai E, Ojima H, Kanai Y, Saito H.
Cancer Sci. 2014 Oct;105(10):1254-60.
http://www.ncbi.nlm.nih.gov/pubmed/25117675

Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA.
Kohno T, Tsuge M, Murakami E, Hiraga N, Abe H, Miki D, Imamura M, Ochi H, Hayes CN, Chayama K.
J Viral Hepat. 2014;21(9):e89-97.
http://www.ncbi.nlm.nih.gov/pubmed/24835118

Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells.
Ono M, Kosaka N, Tominaga N, Yoshioka Y, Takeshita F, Takahashi RU, Yoshida M, Tsuda H, Tamura K, Ochiya T.
Sci Signal. 2014 Jul 1;7(332)
http://www.ncbi.nlm.nih.gov/pubmed/24985346

Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells.
Hibino S, Saito Y, Muramatsu T, Otani A, Kasai Y, Kimura M, Saito H.
Oncogenesis. 2014 May 26;3:e104.
http://www.ncbi.nlm.nih.gov/pubmed/24861464

miR-192 Induces G2/M Growth Arrest in Aristolochic Acid Nephropathy.
Jenkins RH, Davies LC, Taylor PR, Akiyama H, Cumbes B, Beltrami C, Carrington CP, Phillips AO, Bowen T, Fraser DJ.
Am J Pathol. 2014 Apr;184(4):996-1009.
http://www.ncbi.nlm.nih.gov/pubmed/24508230

Myostatin signaling regulates Akt activity via the regulation of miR-486 expression.
Hitachi K, Nakatani M, Tsuchida K.
Int J Biochem Cell Biol. 2014 Feb;47:93-103.
http://www.ncbi.nlm.nih.gov/pubmed/24342526

Downregulation of miR-15a due to LMP1 promotes cell proliferation and predicts poor prognosis in nasal NK/T-cell lymphoma.
Komabayashi Y, Kishibe K, Nagato T, Ueda S, Takahara M, Harabuchi Y.
Am J Hematol. 2014 Jan;89(1):25-33.
http://www.ncbi.nlm.nih.gov/pubmed/23963825

Role of aquaporin-5 in gallbladder carcinoma.
Sekine S, Shimada Y, Nagata T, Sawada S, Yoshioka I, Matsui K, Moriyama M, Omura T, Osawa S, Shibuya K, Hashimoto I, Watanabe T, Hojo S, Hori R, Okumura T, Yoshida T, Tsukada K.
Eur Surg Res. 2013;51(3-4):108-17.
http://www.ncbi.nlm.nih.gov/pubmed/24217644

B-cell malignancies in microRNA Eµ-miR-17~92 transgenic mice.
Sandhu SK, Fassan M, Volinia S, Lovat F, Balatti V, Pekarsky Y, Croce CM.
Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18208-13.
http://www.ncbi.nlm.nih.gov/pubmed/24145403

Expression profiling of ETO2-regulated miRNAs in erythroid cells: Possible influence on miRNA abundance.
Fujiwara T, Okitsu Y, Katsuoka Y, Fukuhara N, Onishi Y, Ishizawa K, Harigae H.
FEBS Open Bio. 2013 Oct 11;3:428-32.
http://www.ncbi.nlm.nih.gov/pubmed/24251106

The flavonoid apigenin improves glucose tolerance through inhibition of microRNA maturation in miRNA103 transgenic mice.
Ohno M, Shibata C, Kishikawa T, Yoshikawa T, Takata A, Kojima K, Akanuma M, Kang YJ, Yoshida H, Otsuka M, Koike K.
Sci Rep. 2013 Aug 30;3:2553.
http://www.ncbi.nlm.nih.gov/pubmed/23989853

Osteogenic differentiation capacity of human skeletal muscle-derived progenitor cells.
Oishi T, Uezumi A, Kanaji A, Yamamoto N, Yamaguchi A, Yamada H, Tsuchida K.
PLoS One. 2013;8(2):e56641.
http://www.ncbi.nlm.nih.gov/pubmed/23457598

MiR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.
Endo Y, Toyama T, Takahashi S, Yoshimoto N, Iwasa M, Asano T, Fujii Y, Yamashita H.
Endocr Relat Cancer. 2013 Feb 18;20(1):91-102.
http://www.ncbi.nlm.nih.gov/pubmed/23183268

Identification of miR-30d as a novel prognostic maker of prostate cancer.
Kobayashi N, Uemura H, Nagahama K, Okudela K, Furuya M, Ino Y, Ito Y, Hirano H, Inayama Y, Aoki I, Nagashima Y, Kubota Y, Ishiguro H.
Oncotarget. 2012 Nov;3(11):1455-71.
http://www.ncbi.nlm.nih.gov/pubmed/23231923

MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis.
Ogawa T, Enomoto M, Fujii H, Sekiya Y, Yoshizato K, Ikeda K, Kawada N.
Gut. 2012 Nov;61(11):1600-9. 
http://www.ncbi.nlm.nih.gov/pubmed/22267590

Clinical significance of miR-144-ZFX axis in disseminated tumour cells in bone marrow in gastric cancer cases.
Akiyoshi S, Fukagawa T, Ueo H, Ishibashi M, Takahashi Y, Fabbri M, Sasako M, Maehara Y, Mimori K, Mori M.
Br J Cancer. 2012 Oct 9;107(8):1345-53. 
http://www.ncbi.nlm.nih.gov/pubmed/22955854

Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells.
Ichikawa T, Sato F, Terasawa K, Tsuchiya S, Toi M, Tsujimoto G, Shimizu K.
PLoS One. 2012;7(2):e31422. 
http://www.ncbi.nlm.nih.gov/pubmed/22384020

Unraveling the global microRNAome responses to ionizing radiation in human embryonic stem cells.
Sokolov MV, Panyutin IV, Neumann RD.
PLoS One. 2012;7(2):e31028. 
http://www.ncbi.nlm.nih.gov/pubmed/22347422

Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage.
Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, Kinoshita M, Watanabe S, Baba O, Kojima Y, Shizuta S, Imai M, Tamura T, Kita T, Kimura T.
Circ Cardiovasc Genet. 2011 Aug 1;4(4):446-54. 
http://www.ncbi.nlm.nih.gov/pubmed/21642241

miR-22 represses cancer progression by inducing cellular senescence.
Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A, Matsunaga J, Takahashi RU, Takata T, Shimamoto A, Ochiya T, Tahara H.
J Cell Biol. 2011 Apr 18;193(2):409-24.
http://www.ncbi.nlm.nih.gov/pubmed/21502362

Identification of altered MicroRNA expression patterns in synovial sarcoma.
Hisaoka M, Matsuyama A, Nagao Y, Luan L, Kuroda T, Akiyama H, Kondo S, Hashimoto H.
Genes Chromosomes Cancer. 2011 Mar;50(3):137-45. 
http://www.ncbi.nlm.nih.gov/pubmed/21213367

MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria.
Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, Takizawa S, Tsuchiya S, Tsujimoto G, Uemoto S, Shimizu K.
PLoS One. 2011 Jan 27;6(1):e16435.
http://www.ncbi.nlm.nih.gov/pubmed/21298008

MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1).
Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, Sakai Y, Shimizu K, Tsujimoto G.
J Biol Chem. 2011 Jan 7;286(1):420-8. 
http://www.ncbi.nlm.nih.gov/pubmed/21044961

The microRNA miR-696 regulates PGC-1{alpha} in mouse skeletal muscle in response to physical activity.
Aoi W, Naito Y, Mizushima K, Takanami Y, Kawai Y, Ichikawa H, Yoshikawa T.
Am J Physiol Endocrinol Metab. 2010 Apr;298(4):E799-806
http://www.ncbi.nlm.nih.gov/pubmed/20086200